These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9087382)

  • 1. Human cytotoxic CD8+ T-lymphocyte clones engraft in severe combined immunodeficient (SCID) mice but show diminished function.
    de Kroon JF; van Bergen CA; de Paus RA; Kluin-Nelemans HC; Willemze R; Falkenburg JH
    J Immunother; 1997 Mar; 20(2):101-10. PubMed ID: 9087382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
    Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK
    Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
    Alderson MR; Sassenfeld HM; Widmer MB
    J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
    Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
    Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
    Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
    Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency.
    Malkovska V; Cigel FK; Armstrong N; Storer BE; Hong R
    Cancer Res; 1992 Oct; 52(20):5610-6. PubMed ID: 1394184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
    Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
    Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1.
    Shpitz B; Chambers CA; Singhal AB; Hozumi N; Fernandes BJ; Roifman CM; Weiner LM; Roder JC; Gallinger S
    J Immunol Methods; 1994 Feb; 169(1):1-15. PubMed ID: 7907638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency.
    Murphy WJ; Conlon KC; Sayers TJ; Wiltrout RH; Back TC; Ortaldo JR; Longo DL
    J Immunol; 1993 Apr; 150(8 Pt 1):3634-42. PubMed ID: 8468492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen.
    Mami-Chouaib F; Echchakir H; Dorothée G; Vergnon I; Chouaib S
    Immunol Rev; 2002 Oct; 188():114-21. PubMed ID: 12445285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
    Wagar EJ; Cromwell MA; Shultz LD; Woda BA; Sullivan JL; Hesselton RM; Greiner DL
    J Immunol; 2000 Jul; 165(1):518-27. PubMed ID: 10861091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive transfer of low numbers of CD4+ T cells into SCID mice chronically treated with soluble IL-4 receptor does not prevent engraftment of IL-4-producing T cells.
    Rudolphi A; Enssle KH; Claesson MH; Reimann J
    Scand J Immunol; 1993 Jul; 38(1):57-64. PubMed ID: 8327860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL.
    Cullup H; Hsu AK; Kassianos AJ; McDonald K; Radford KJ; Rice AM
    J Immunother; 2011 May; 34(4):362-71. PubMed ID: 21499125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
    Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
    J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal analysis of the peripheral T cell compartment of the SCID-hu mouse.
    Vandekerckhove BA; Krowka JF; McCune JM; de Vries JE; Spits H; Roncarolo MG
    J Immunol; 1991 Jun; 146(12):4173-9. PubMed ID: 1674954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy.
    Mealey RH; Littke MH; Leib SR; Davis WC; McGuire TC
    Vet Immunol Immunopathol; 2008 Jan; 121(1-2):8-22. PubMed ID: 17727961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of primary antigen-specific human cytotoxic T lymphocytes in human/mouse radiation chimera.
    Segall H; Lubin I; Marcus H; Canaan A; Reisner Y
    Blood; 1996 Jul; 88(2):721-30. PubMed ID: 8695821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and functional heterogeneity of thymic and splenic lymphokine activated killer cells relative to ornithine sensitivity.
    Mehrotra P; Bear HD; Susskind BM
    Cell Immunol; 1991 Feb; 132(2):451-65. PubMed ID: 1899052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.